Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The most recent 2017 World Health Organization (WHO) classification of pancreatic neuroendocrine neoplasms (PanNENs) has refined the three-tiered 2010 scheme by separating grade 3 pancreatic neuroendocrine tumors (G3 PanNETs) from poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs). However, differentiating between G3 Pan- NETs and PanNECs is difficult in clinical practice. Materials and Methods Eighty-two surgically resected PanNENs were collected from 16 institutions and reclassified according to the 2017 WHO classification based on the histological features and proliferation index (mitosis and Ki-67). Immunohistochemical stains for ATRX, DAXX, retinoblastoma, p53, Smad4, p16, and MUC1 were performed for 15 high-grade PanNENs. Results Re-classification resulted in 20 G1 PanNETs (24%), 47 G2 PanNETs (57%), eight G3 welldifferentiated PanNETs (10%), and seven poorly differentiated PanNECs (9%). PanNECs showed more frequent diffuse nuclear atypia, solid growth patterns and apoptosis, less frequent organoid growth and regular vascular patterns, and absence of low-grade PanNET components than PanNETs. The Ki-67 index was significantly higher in PanNEC (58.2%± 15.1%) compared to G3 PanNET (22.6%±6.1%, p < 0.001). Abnormal expression of any two of p53, p16, MUC1, and Smad4 could discriminate PanNECs from G3 PanNETs with 100% specificity and 87.5% sensitivity. Conclusion Histological features supporting the diagnosis of PanNECs over G3 PanNETs were the absence of a low-grade PanNET component in the tumor, the presence of diffuse marked nuclear atypia, solid growth pattern, frequent apoptosis and markedly increased proliferative activity with homogeneous Ki-67 labeling. Immunohistochemical stains for p53, p16, MUC1, and Smad4 may be helpful in distinguishing PanNECs from G3 PanNETs in histologically ambiguous cases, especially in diagnostic practice when only small biopsied tissues are available.
Abstract
Purpose The most recent 2017 World Health Organization (WHO) classification of pancreatic neuroendocrine neoplasms (PanNENs) has refined the three-tiered 2010 scheme by separating grade 3 pancreatic neuroendocrine tumors (G3 PanNETs) from poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs). However, differentiating between G3 Pan- NETs and PanNECs is difficult in clinical practice. Materials and Methods Eighty-two surgically resected PanNENs were collected from 16 institutions and reclassified according to the 2017 WHO classification based on the histological features and proliferation index (mitosis and Ki-67). Immunohistochemical stains for ATRX, DAXX, retinoblastoma, p53, Smad4, p16, and MUC1 were performed for 15 high-grade PanNENs. Results Re-classification resulted in 20 G1 PanNETs (24%), 47 G2 PanNETs (57%), eight G3 welldifferentiated PanNETs (10%), and seven poorly differentiated PanNECs (9%). PanNECs showed more frequent diffuse nuclear atypia, solid growth patterns and apoptosis, less frequent organoid growth and regular vascular patterns, and absence of low-grade PanNET components than PanNETs. The Ki-67 index was significantly higher in PanNEC (58.2%± 15.1%) compared to G3 PanNET (22.6%±6.1%, p < 0.001). Abnormal expression of any two of p53, p16, MUC1, and Smad4 could discriminate PanNECs from G3 PanNETs with 100% specificity and 87.5% sensitivity. Conclusion Histological features supporting the diagnosis of PanNECs over G3 PanNETs were the absence of a low-grade PanNET component in the tumor, the presence of diffuse marked nuclear atypia, solid growth pattern, frequent apoptosis and markedly increased proliferative activity with homogeneous Ki-67 labeling. Immunohistochemical stains for p53, p16, MUC1, and Smad4 may be helpful in distinguishing PanNECs from G3 PanNETs in histologically ambiguous cases, especially in diagnostic practice when only small biopsied tissues are available.
참고문헌 (19)
- Kloppel G, "WHO classification of tumours of endocrine organs", pp.211~214 (2017), IARC Press
- Klimstra DS, "WHO classification of tumours of the digestive system", pp.322~326 (2010), IARC Press
- Basturk O, "The high-grade(WHO G3)pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms", Am J Surg Pathol, 39, pp.683~690 (2015)
- Tang LH, "Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component : a pathway distinct from poorly differentiated neuroendocrine carcinomas", Clin Cancer Res, 22, pp.1011~1017 (2016)
- Jiao Y, "DAXX", ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors, 2011, pp.331, 1199~1203
- Yachida S, "Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors", Am J Surg Pathol, 36, pp.173~184 (2012)
- Raj N, "Treatment response and outcomes of grade 3 pancreatic neuroendocrine neoplasms based on morphology : well differentiated versus poorly differentiated", Pancreas, 46, pp.296~301 (2017)
- Adsay NV, "WHO classification of tumours of endocrine organs", pp.235~237 (2017), IARC Press
- Heetfeld M, "Characteristics and treatment of patients with G3gastroenteropancreatic neuroendocrine neoplasms", Endocr Relat Cancer, 22, pp.657~664 (2015)
- Zee SY, "Pleomorphic pancreatic endocrine neoplasms : a variant commonly confused with adenocarcinoma", Am J Surg Pathol, 29, pp.1194~1200 (2005)
- Konukiewitz B, "Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20", Mod Pathol, 30, pp.587~598 (2017)
- Konukiewitz B, "Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3", Hum Pathol, 77, pp.70~79 (2018)
- Kakar S, "AJCC cancer staging manual", pp.337~347 (2017), Springer
- Hwang HS, "Grading by the Ki-67 labeling index of endoscopic ultrasoundguided fine needle aspiration biopsy specimens of pancreatic neuroendocrine tumors can be underestimated", Pancreas, 47, pp.1296~1303 (2018)
- Tang LH, "A practical approach to the classification of WHO grade 3(G3)well-differentiated neuroendocrine tumor(WD-NET)and poorly differentiated neuroendocrine carcinoma(PD-NEC)of the pancreas", Am J Surg Pathol, 40, pp.1192~1202 (2016)
- Kim JY, "Alternative lengthening of telomeres in primary pancreatic neuroendocrine tumors is associated with aggressive clinical behavior and poor survival", Clin Cancer Res, 23, pp.1598~1606 (2017)
- Kim JY, "Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival", Virchows Arch, 472, pp.739~748 (2018)
- 김성주, "Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients", Journal of Pathology and Translational Medicine, 51(4), pp.388~395 (2017), 대한병리학회[DOI]
- Grillo F, "Immunohistochemistry on old archival paraffin blocks:is there an expiry date?", J Clin Pathol, 70, pp.988~993 (2017)